Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial Chemotherapy for ACPP and CPC Prior to Second-Look Surgery
NCT04994977Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan, carboplatin and topotecan in choroid plexus papilloma (CPP) and choroid plexus carcinoma (CPC), sponsored by Weill Cornell Medicine. Primary endpoint: Number of Serious Adverse Events at 6 months. Started May 2023; status: terminated.
02
Drugs
melphalancarboplatintopotecan
03
Conditions
choroid plexus papilloma (CPP)choroid plexus carcinoma (CPC)
Beyond the preview
Go deeper on NCT04994977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994977.